RESULTS OF A PHASE 1 STUDY OF BMN 673, A POTENT AND SPECIFIC PARP-1/2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES

被引：0
|
作者：
Mufti, G. J. [1 ]
Estey, E. [2 ]
Popat, R. [3 ]
Mattison, R. [4 ]
Menne, T. [5 ]
Azar, J. [6 ]
Bloor, A. [7 ]
Gaymes, T. [1 ]
Khwaja, A. [3 ]
Juckett, M. [4 ]
Lennard, A. [5 ]
Zhang, C. [8 ]
Gallant, G. J. A. [8 ]
Gopal, A. K. [2 ]
机构：
[1] Kings Coll Hosp NHS Fdn Trust, London, England
[2] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[3] UCL, Inst Canc, London, England
[4] Univ Wisconsin, Madison, WI USA
[5] Newcastle Upon Tyne NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England
[6] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[7] Christie Hosp NHS Trust, Manchester, Lancs, England
[8] BioMarin Pharmaceut Inc, Novato, CA USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P180
引用
收藏
页码：33 / 34
页数：2
相关论文
共 50 条
  • [21] Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
    Mittra, Arjun
    Coyne, Geraldine H. O' Sullivan
    Zlott, Jennifer
    Kummar, Shivaani
    Meehan, Robert
    Rubinstein, Lawrence
    Juwara, Lamin
    Wilsker, Deborah
    Ji, Jiuping
    Miller, Brandon
    Navas, Tony
    Ferry-Galow, Katherine V.
    Voth, Andrea Regier
    Chang, Ting-Chia
    Jiwani, Shahanawaz
    Parchment, Ralph E.
    Doroshow, James H.
    Chen, Alice P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (03) : 177 - 189
  • [22] PARP inhibition with BMN 673 in ovarian and breast cancer patients with deleterious mutations of BRCA1 and BRCA2
    Ramanathan, R.
    Wainberg, Z.
    Mina, L.
    Byers, L.
    Chugh, R.
    Zhang, C.
    Henshaw, J.
    Dorr, A.
    de Bono, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S13 - S13
  • [23] ABRAZO: An international phase 2 (2-stage, 2-cohort) study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer
    Turner, N. C.
    Balmana, J.
    Fasching, P. A.
    Hurvitz, S. A.
    Rugo, H. S.
    Telli, M. L.
    Visco, F.
    Wardley, A. M.
    Yang, X.
    Lokker, N. A.
    Lounsbury, D. L.
    Robson, M. E.
    CANCER RESEARCH, 2016, 76
  • [24] Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone
    Aoyagi-Scharber, Mika
    Gardberg, Anna S.
    Yip, Bryan K.
    Wang, Bing
    Shen, Yuqiao
    Fitzpatrick, Paul A.
    ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS, 2014, 70 : 1143 - 1149
  • [25] Pharmacokinetics and pharmacodynamics of pemigatinib, a potent and selective inhibitor of FGFR 1, 2, and 3, in patients with advanced malignancies
    Ji, Tao
    Lihou, Christine
    Asatiani, Ekaterine
    Feliz, Luis
    Overholt, Heather
    Landman, Robert
    Chen, Xuejun
    Yeleswaram, Swamy
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [26] Preclinical characterization of NMS-P648, a novel and potent PARP-1/-3 inhibitor
    Montagnoli, Alessia
    Papeo, Gianluca
    Rainoldi, Sonia
    Cirla, Alessandra
    Ciavolella, Antonella
    Albanese, Clara
    Modugno, Michele
    Bosotti, Roberta
    Somaschini, Alessio
    Carapezza, Giovanni
    Lupi, Rosita
    Ballinari, Dario
    Ciomei, Marina
    Pesenti, Enrico
    Donati, Daniele
    Isacchi, Antonella
    Galvani, Arturo
    CANCER RESEARCH, 2015, 75
  • [27] Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
    Gunderson, Camille C.
    Moore, Kathleen N.
    FUTURE ONCOLOGY, 2015, 11 (05) : 747 - 757
  • [28] A phase 1/2 study of talazoparib (BMN 673), an oral poly(ADP-ribose) polymerase inhibitor, plus temozolomide in children with refractory or recurrent malignancies: A Children's Oncology Group phase 1 consortium study (ADVL1411)
    Schafer, E. S.
    Rau, R. E.
    Liu, X.
    Minard, C. G.
    Reid, J. M.
    Fox, E.
    Weigel, B. J.
    Blaney, S. M.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S48 - S48
  • [29] Identification and mechanism of action analysis of the new PARP-1 inhibitor 2"-hydroxygenkwanol A
    Dal Piaz, Fabrizio
    Ferro, Piera
    Vassallo, Antonio
    Vasaturo, Michele
    Forte, Giovanni
    Chini, Maria Giovanna
    Bifulco, Giuseppe
    Tosco, Alessandra
    De Tommasi, Nunziatina
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2015, 1850 (09): : 1806 - 1814
  • [30] Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies
    Vergote, I. B.
    Lund, B.
    Peen, U.
    Umajuridze, Z.
    Mau-Sorensen, M.
    Kranich, A.
    Van Nieuwenhuysen, E.
    Haslund, C.
    Nottrup, T.
    Han, S. N.
    Concin, N.
    Unger, T. J.
    Chai, Y.
    Au, N.
    Rashal, T.
    Joshi, A.
    Crochiere, M.
    Landesman, Y.
    Shah, J.
    Shacham, S.
    Kauffman, M.
    Mirza, M. R.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (02) : 308 - 314
12345